# Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

> **NCT02239380** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 26 (actual)

## Conditions studied

- Status Epilepticus

## Interventions

- **DRUG:** Lorazepam

## Key facts

- **NCT ID:** NCT02239380
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239380, "Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02239380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*